Pet Diabetes Management Market Forecasts to 2034 - Global Analysis By Animal Type (Dogs, Cats), Care Component, Care Setting, Distribution Channel, Monitoring Method, Disease Management Stage, and By Geography

According to Stratistics MRC, the Global Pet Diabetes Management Market is accounted for $2.5 billion in 2026 and is expected to reach $5.0 billion by 2034 growing at a CAGR of 9.1% during the forecast period. The market covers the diagnosis, monitoring and long-term management of diabetes in dogs and cats, including veterinary insulin regimens, glucose meters and sensors, and prescription diets. It is used to help clinicians and owners maintain glycemic control and identify complications earlier. Growth reflects rising chronic-disease detection and improved home monitoring and longer companion-animal lifespans.

Market Dynamics:

Driver:

Rising diabetes diagnosis and advances in glucose monitoring

Rising diabetes prevalence in dogs and cats, greater veterinary screening, and stronger owner awareness are expanding demand for insulin therapies, glucose monitors, prescription diets and monitoring consumables. Continuous glucose sensors, capillary meters and urine ketone testing are improving at-home glycemic control and earlier detection of complications. Longer companion-animal lifespans and higher per-pet spending support sustained treatment. Clinics and owners increasingly seek convenient, reliable tools that fit daily routines, supporting repeat purchases across diagnosis, stabilization and long-term management.

Restraint:

Lifelong treatment cost and owner adherence challenges

Managing pet diabetes requires lifelong insulin, consistent monitoring, prescription nutrition and regular veterinary review, creating ongoing costs that can discourage owners, particularly in multi-pet or price-sensitive households. Insulin storage, dosing accuracy, sensor replacement and visit frequency add complexity. Owners may struggle to interpret readings or maintain schedules, reducing outcomes and repeat purchase consistency. Uneven access to specialist endocrinology expertise and variable product availability across regions further constrain adoption, while reimbursement remains limited outside insured pet populations.

Opportunity:

Connected monitoring and individualized care pathways

Connected glucose sensors, mobile apps and veterinary portals can link home readings with clinical review, enabling earlier intervention and better adherence. Integrating insulin, diets and consumables into structured care plans supports bundle sales and retention. Practitioner partnerships, online pet pharmacies and teleconsultation extend reach beyond urban clinics. There is scope for size- and species-specific devices, owner education and reminder systems, plus insurer collaboration to improve affordability. Providers combining credible evidence, convenience and coordinated veterinary support can differentiate in a crowded, price-sensitive category.

Threat:

Product reliability, treatment complexity and price competition

Inconsistent sensor accuracy, insulin handling errors and variable veterinary protocols can undermine owner confidence and clinical outcomes. Lower-priced substitutes, unregulated online sellers and inconsistent product claims pressure margins and complicate purchasing decisions. Regulatory variation across markets affects device approval and labeling. Shortages of trained veterinary staff and specialist endocrinology capacity can limit adoption of advanced monitoring. Manufacturers must maintain quality, traceability and clear guidance while demonstrating measurable glycemic benefits to sustain veterinary endorsement and owner trust.

Covid-19 Impact:

The COVID-19 pandemic disrupted veterinary appointments, specialist retail, travel and pet-care supply chains, while shifting more purchasing and advice-seeking online. Some owners postponed non-urgent services, but increased time at home and heightened attention to animal wellbeing supported demand for home-use products and digital support. Providers responded with e-commerce, teleconsultation and flexible scheduling. As restrictions eased, in-person services recovered, but demand for convenience and clear product information remained. The effect varied by market, depending on clinical need, discretionary spending and reliance on in-person experiences where available.

The Dogs segment is expected to be the largest during the forecast period

The Dogs segment is expected to account for a leading share of the pet diabetes management market during the forecast period. Its position reflects the relevance of this group to the addressable companion-animal population and the breadth of use across the market's principal animal type applications. Established product availability, owner familiarity and professional recommendations support demand, while a wide range of care needs encourages repeat purchasing or service use. Market participants are expected to prioritize this segment through targeted product development, broader distribution and clearer use guidance.

The Monitoring Consumables segment is expected to have the highest CAGR during the forecast period

The Monitoring Consumables segment is expected to have the highest CAGR during the forecast period as providers expand targeted solutions and improve access through veterinary, specialist retail and digital channels. Demand is supported by growing awareness of the relevant need, improved product formulation or service delivery, and increased owner willingness to invest in tailored companion-animal care. As evidence, convenience and availability improve, this segment may attract new entrants and encourage established providers to broaden their portfolios.

Region with largest share:

North America is expected to account for a leading share of the pet diabetes management market, supported by high companion-animal ownership, comparatively developed veterinary infrastructure, established pet specialty retail and relatively high per-pet expenditure. The United States represents a major demand center because owners have access to veterinary clinics, online pet-care platforms and a broad selection of specialized products and services. Canada contributes through a mature pet-care ecosystem and established companion-animal health providers. Market adoption is also supported by insurance availability, consumer awareness and product innovation, although adoption differs by income, geography and veterinary access.

Region with highest CAGR:

Asia Pacific is expected to exhibit strong growth in the pet diabetes management market as pet ownership, urban household formation, veterinary service availability and organized pet retail expand across major markets. China, Japan, South Korea, India and Australia offer different adoption pathways, reflecting differences in purchasing power, veterinary infrastructure, product regulation and the role of digital commerce. Growing awareness of preventive care and rising demand for premium companion-animal products are likely to support market development. Expansion will depend on localized products, professional education and compliance with national animal-health and consumer-protection requirements.

Key players in the market

Some of the key players in the Global Pet Diabetes Management Market include Zoetis Inc., Boehringer Ingelheim Animal Health, Merck Animal Health, Elanco Animal Health, Dechra Pharmaceuticals PLC, Virbac, Vetoquinol, IDEXX Laboratories, Inc., Antech Diagnostics, Abbott Laboratories, Becton, Dickinson and Company, i-SENS, Inc., PetTest, Covetrus, Inc., Hill's Pet Nutrition, Trividia Health, Inc..

Key Developments:

In September 2026, American Animal Hospital Association released updated canine diabetes-management guidelines covering diagnosis, insulin treatment, continuous glucose monitoring, dietary management and follow-up care.

In May 2026, ALR Technologies SG Ltd. made its GluCurve continuous glucose monitoring system available in Canada for dogs and cats, providing frequent readings through a pet-specific sensor, mobile app and veterinary portal.

In April 2026, American Animal Hospital Association issued updated feline diabetes guidelines addressing SGLT2-inhibitor therapy, insulin protocols and expanded continuous glucose monitoring for cats.

Animal Types Covered:

• Dogs
• Cats

Care Components Covered:

• Insulin and Glucose-Lowering Therapies
• Glucose Monitoring Devices
• Prescription Diets
• Monitoring Consumables

Care Settings Covered:

• Veterinary Hospitals and Clinics
• Specialty Veterinary Endocrinology Practices
• Home-Based Monitoring

Distribution Channels Covered:

• Veterinary Pharmacies
• Retail Pharmacies
• Online Pet Pharmacies

Monitoring Methods Covered:

• Continuous Glucose Monitoring Sensors
• Capillary Blood Glucose Meters
• Urine Glucose and Ketone Testing

Disease Management Stages Covered:

• Initial Diagnosis and Stabilization
• Long-Term Glycemic Management
• Complication and Comorbidity Management

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
    • Saudi Arabia
    • United Arab Emirates
    • Qatar
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Egypt
    • Morocco
    • Rest of Africa

What our report offers:

• Market share assessments for regional and country-level segments
• Strategic recommendations for new entrants
• Covers market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032, and 2034
• Market trends, including drivers, constraints, opportunities, threats, challenges, investment opportunities, and recommendations
• Strategic recommendations for key business segments based on market estimations
• Competitive landscape mapping and assessment of key industry trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends and assessment of the latest technological advancements

Free Customization Offerings:

All customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, forecasts, and CAGR of any prominent country as per the client's interest (subject to feasibility assessment)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances